Literature DB >> 15761752

Designing the most favourable study design.

Silvio Garattini1.   

Abstract

Mesh：

Year:  2005        PMID： 15761752     DOI： 10.1007/s00228-005-0895-8

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  5 in total

1.  Light and shade in proposed revision of EU drug-regulatory legislation.

Authors:  Silvio Garattini; Vittorio Bertele'; Luca Li Bassi
Journal:  Lancet       Date:  2003-02-22       Impact factor: 79.321

2.  European Council waters down European Parliament's drug-regulatory legislation.

Authors:  Silvio Garattini; Vittorio Bertele'; Luca Li Bassi
Journal:  Lancet       Date:  2003-11-22       Impact factor: 79.321

Review 3.  Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis.

Authors:  Bruce M Psaty; Curt D Furberg; Wayne A Ray; Noel S Weiss
Journal:  JAMA       Date:  2004-11-22       Impact factor: 56.272

4.  Statistical power, sample size, and their reporting in randomized controlled trials.

Authors:  D Moher; C S Dulberg; G A Wells
Journal:  JAMA       Date:  1994-07-13       Impact factor: 56.272

5.  Risk of cardiovascular events and rofecoxib: cumulative meta-analysis.

Authors:  Peter Jüni; Linda Nartey; Stephan Reichenbach; Rebekka Sterchi; Paul A Dieppe; Matthias Egger
Journal:  Lancet       Date:  2004 Dec 4-10       Impact factor: 79.321
  5 in total
  1 in total

1.  Modelling of the outcome of non-inferiority trials by integration of historical data.

Authors:  Alberto Russu; Erik van Zwet; Giuseppe De Nicolao; Oscar Della Pasqua
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-08-21       Impact factor: 2.745
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.